Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: Adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model
Geriatrics and Gerontology International,  Clinical Article

Shinozaki T et al. - The use of atorvastatin to lower cholesterol levels in elderly Japanese patients with type 2 diabetes mellitus appears to reduce the risk of cardiovascular and diabetes-related events.

Methods
  • Data were obtained from 1173 patients aged 65–84 years who were enrolled in the J–EDIT.
  • Patients were followed prospectively for 6 years to determine the effects of atorvastatin on serum cholesterol levels, and cardiovascular and diabetes–related events.
  • Because the study protocol allowed atorvastatin to be prescribed according to the clinical needs of each patient, the authors regarded the J–EDIT data as if they came from a cohort study.
  • The authors adjusted for clinical characteristics during the study as time–dependent confounders using two methods, inverse–probability–of–treatment (IPT) weighting and g–estimation method.
  • The total follow–up period was 5310.8 person–years (5.7 years of median follow up), during which 202 patients received atorvastatin treatment.
  • Atorvastatin was associated with moderate reductions in cholesterol levels: 24.2 mg/dL for total cholesterol, 22.9 mg/dL for low–density lipoprotein (LDL) cholesterol and 24.3 mg/dL for non–high–density lipoprotein cholesterol at the first post–treatment year.

Results
  • As a result, the proportion of patients who achieved targeted levels of LDL cholesterol clearly increased after atorvastatin treatment.
  • Eight patients in 476.6 person–years among atorvastatin–treated and 113 untreated patients in 4721.4 person–years had cardiovascular events (the composite end–point of fatal/non–fatal myocardial infarction, angina pectoris, coronary intervention, and fatal/non–fatal cerebrovascular disease); hazard ratio (HR) = 0.48, 95% confidence interval (CI) = 0.19–1.16, P = 0.10, and HR = 0.32, 95% CI = 0.05–1.87, P = 0.21 from IPT weighting and g–estimation method, respectively.
  • Furthermore, seven in 475.0 person–years among atorvastatin–treated and 149 untreated patients in 4682.4 person–years had diabetes–related events (the composite end–point of sudden death, renal failure death, death as a result of hyperglycemia or hypoglycemia, diabetic gangrene and congestive heart failure in addition to cardiovascular event); HR = 0.30, 95% CI = 0.12–0.77, P = 0.01, and HR = 0.40, 95% CI = 0.09–0.89, P = 0.03 from IPT weighting and g–estimation method, respectively.
  • When cardiovascular events were further differentiated into coronary vascular and cerebrovascular events, atorvastatin especially decreased the cerebrovascular risk.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

2 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

5 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

6 Magnesium should be given to all children presenting to hospital with acute severe asthma Paediatric Respiratory Reviews, October 15, 2014    Clinical Article

7 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

8 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

9 Buccal acetaminophen provides fast analgesia: two randomized clinical trials in healthy volunteers Full Text Drug Design, Development and Therapy, September 30, 2014    Free full text    Clinical Article

10 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

13 Honey: a potential therapeutic agent for managing diabetic wounds Full Text Evidence-based Complementary and Alternative Medicine , October 16, 2014    Free full text    Clinical Article

14 Differences in composition of honey samples and their impact on the antimicrobial activities against drug multiresistant bacteria and pathogenic fungi Archives of Medical Research, October 3, 2014    Clinical Article

15 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

16 Update on recommendations for use of herpes zoster vaccine Full Text Morbidity and Mortality Weekly Report, August 22, 2014    Free full text

17 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

18 Effect of reiki therapy on pain and anxiety in adults: an in-depth literature review of randomized trials with effect size calculations Pain Management Nursing, October 2, 2014    Clinical Article

19 Dapoxetine for premature ejaculation: an updated meta-analysis of randomized controlled trials Clinical Therapeutics, October 29, 2014    Clinical Article

20 What's more effective: Generic or brand-name statins? Brigham and Women's Hospital, September 16, 2014

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore